Novavax Lifts 2026 Revenue Outlook by $145M on Sanofi Milestone
Image
Gaithersburg – November 05, 2026 -- Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point, after earning a $125 million milestone from partner Sanofi and cutting its quarterly net loss to $31 million from $202 million a year earlier.
Sanofi's European Phase 3 start triggers $125 million payment
Novavax earned the payment in October, when Sanofi initiated a Phase 3 trial of its influenza-COVID-19 combination (CIC) vaccine in Europe. Sanofi has confirmed it intends to start a U.S. Phase 3 CIC trial in 2027 to support U.S. approval.